CTRI/2020/05/025299已完成2 期
Convalescent Plasma to Limit Coronavirus Associated Complications: An Open label Clinical Study of Anti-SARS-CoV-2 Plasma in Hospitalized Patients with COVID-19
Wockhardt Ltd0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or female, aged between 18 to 75 years (both inclusive)
- •2.Hospitalized with RT-PCR confirmed COVID-19 illness and has any one of the below mentioned two:
- •PaO2/ FiO2 <300
- •Respiratory Rate > 24/min and SaO2 < 93% on room air
- •3.Subject or LAR agree to provide a signed written informed consent prior to any study specific procedures and also agree to comply with study requirements
排除标准
- •Exclusion Criteria:
- •1.Receipt of pooled immunoglobulin in past 30 days
- •2.Contraindication to transfusion or history of prior reactions to transfusion blood products
- •3.Critically ill patients:
- •PaO2/ FiO2 ratio <200 (moderate - severe ARDS)
- •4.Participating in any other clinical trial
- •5.Clinical status precluding infusion of blood products
- •6.Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period
研究者
相似试验
已完成
3 期
Convalescent plasma from cured coronavirus disease (COVID) patients as a therapy for patients with severe COVID disease (CONCOVID)CoronavirusCOVID-19SARS-CoV-210047438NL-OMON50016Erasmus MC, Universitair Medisch Centrum Rotterdam87
撤回
2 期
Convalescent Plasma to Limit Coronavirus Associated ComplicationsCoronavirusNCT04325672Mayo Clinic
招募中
不适用
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical TrialCOVID-19.Coronavirus infection, unspecifiedB34.2IRCT20181104041551N1Mazandaran University of Medical Sciences30
撤回
1 期
Study Testing Convalescent Plasma vs Best Supportive CarePneumonia, InterstitialNCT04333251Baylor Research Institute115
招募中
不适用
se of Convalescent Plasma in the treatment of COVID-19IRCT20200414047072N1Hilton Pharma Pvt. Ltd.357